Adult Dosing
Advanced prostate carcinoma, palliative therapy
- 3.75 mg IM q4 wks
- Alt: 11.25 mg IM q12 wks or 22.5 mg IM q24 wks
- Notes: Reconstitute microgranules in sterile water; do not use any other diluent
- Dosage strengths are not additive, select strength based on desired dosing schedule
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
- There have been rare reports of anaphylactic shock, hypersensitivity and angioedema related to triptorelin administration. Suspend therapy and initiate appropriate medical management if hypersensitivity occurs
- Transient increase in serum testosterone levels leading to worsening of signs and symptoms during first few weeks of therapy has occurred. Worsening of symptoms or onset of new symptoms, including neuropathy, bone pain, urethral or bladder outlet obstruction or hematuria may occur
- Spinal cord compression or renal function impairment reported; institute appropriate therapy, in extreme cases, consider immediate orchiectomy
- In men receiving GnRH agonists, hyperglycemia and an increased risk of developing diabetes may occur. Therefore monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically
- Use of GnRH agonists in men may increase risk of developing myocardial infarction, sudden cardiac death and stroke. Closely monitor for symptoms and signs suggestive of cardiovascular disease
- Avoid concurrent use of hyperprolactinemic drugs
- Monitor serum levels of testosterone and prostate specific antigen
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Metastatic vertebral lesions
- Lower urinary tract obstruction
- Diabetes mellitus risk
- Cardiovascular disease risk
Pregnancy Category:X
Breastfeeding: Unsafe; use not recommended. Potential for serious adverse reactions in nursing infants exists; as per manufacturer's data, a decision should be made for discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
